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Cadmium (Cd) has recently emerged as a major concern not only in environmental tox-
icology but also in metabolic diseases such as diabetes mellitus and its complications. 
Conflicting data aside, these studies have not been examined in a clinical population 
undergoing management as well as possible modulation by the prominent metabolic 
antagonist of Cd such as zinc (Zn). This study examined the relationship between 
cadmium levels, glycemic control, and renal pathology in established type II diabetic 
patients with focus on populations exposed to modern environmental health hazards 
(MEHHs). Sixty-five participants, consisting of 45 type-2 diabetics and 20 non-diabetics 
were enrolled for the study, mean age 61.51 ± 5.27 years. Glycated hemoglobin (HbA1c) 
was used to classify them into three sub-groups: (A) good glycemic control (44.4%), 
(B) fair glycemic control (24.4%), and (C) poor glycemic control (31.1%). Plasma levels of 
glucose, Cd, Zn, HbA1c, creatinine, urinary creatinine, microalbuminuria, and estimated 
glomerular filtration rate (eGFR) were determined in all participants using standard meth-
ods. Fasting plasma glucose was higher in diabetics than in non-diabetics (p = 0.000) 
as well as Zn level, though not significantly. Interestingly, Cd level, Cd/Zn ratio, and 
urinary creatinine were significantly lower in diabetics than in non-diabetics. The group 
with poor glycemic control (C) had significantly higher Cd level compared to the one 
with good glycemic control (group A). The renal function revealed that microalbuminuria 
and urinary albumin/creatinine ratio (UACR) was significantly higher in diabetics than in 
non-diabetics, while eGFR was found to be similar in both diabetics and non-  diabetics. 
UACR inversely correlated with Cd level, while plasma creatinine level positively 
correlated with Cd but not significantly. Correlation between Cd and HbA1c revealed 
non-significant  inverse  correlation (r = −0.007; p > 0.05), while Zn showed a significant 
inverse corr elation with Cd (r = −0.317; p < 0.014). The lower Cd level in diabetics com-
pared to non-diabetics  probably reflects the modulating effect of Zn in treated diabetics 
given nutritional education in addition to their regular regime, including good sources 
of Zn. The renal insufficiency with increasing Cd level may suggest that the progression 
of renal impairment may not be responsive to the putative modulating effect of Zn.
Keywords: cadmium–zinc interaction, glycated hemoglobin, diabetes mellitus, renal function and environmental 
health
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inTrODUcTiOn
Cadmium (Cd) is a non-essential (toxic) metal that is ubiquitous 
in the environment. It is a persistent non-biodegradable toxicant 
with a long biological half life of about 10–30 years (1). It is a 
known metabolic antagonist of zinc, a very essential micronutri-
ent that is vital in many intermediary metabolic and molecular 
events (2, 3). Human exposure to Cd has been associated with 
a number of biological and medical effects that makes it of 
critical importance in biology and medicine. Cadmium has been 
traditionally implicated in renal and hepatic diseases and prob-
ably more internationally as a factor in itai-itai disease, which 
is characterized by renal tubular dysfunction, osteomalacia, 
and pseudo fractures. Very recently, an association between 
cadmium and metabolic diseases has been reported (4).
Indeed, the rising global incidence of diabetes mellitus (DM) 
has been correlated with the rising level of environmental pol-
lution, suggesting that an increase in diabetes may likely occur 
even if the prevalence of obesity is held constant (5). A growing 
body of knowledge consistently suggests the involvement of 
environmental factors in the etiology of type II diabetes, and this 
is also being gradually accepted as at least in part an explanation 
for the global increasing rate of type II DM in both the developed 
and the developing countries (6). Although factors such as 
obesity, body mass index (BMI), diet, and lifestyle have been 
primarily identified as risk factors for diabetes, environmental 
pollutants, of which cadmium is a prime candidate, have been 
consistently linked (7).
Epidemiological studies have shown that there is an associa-
tion between Cd exposure, incidence, severity, and complications 
of DM (8). A number of mechanisms have been adduced for this 
association; Cd apart from being pancreatotoxic also accumulates 
in the pancreas, where it serves as a metabolic antagonist of Zn, 
which potentiates insulin action among others (9).
Experimental studies have shown that Cd elevates fasting 
blood glucose before overt signs of renal dysfunction are evident 
and that Cd acts synergistically with chronic hyperglycemia 
seen in diabetes nephropathy (8). Cadmium is thus consid-
ered to play a crucial role in the progression of DM-related 
kidney disease and more importantly, due to its accumulation 
in other organs, such as the eye, liver, bone, pancreas, and 
nerves (10–12). Any substance that has been implicated in such 
a diverse group of pathological conditions particularly in an 
important one like DM should attract attention and stimulate 
research.
In rapidly industrializing developing countries, environ-
mental Cd level and the incidence of type II diabetes are on 
the increase as well as the incidence of type II DM (13). This 
may be due to the extensive use of cadmium in industries and 
its widespread dispersion in the environment, particularly 
in Nigeria, where owing to progressive industrialization and 
often poor regulation of chemical exposure, may be higher 
and perhaps of greater severity. Hence, a possible link between 
cadmium exposure, DM, and diabetic nephropathy deserve 
exploration. Various studies have focused on the early stage of 
cadmium-induced kidney injury in exposed human populations 
without considering DM (14, 15). Few studies have examined 
clinical cases along with one of the most important long-term 
complications of DM and diabetes nephropathy. Thus, this study 
is designed to examine the relationship between cadmium levels, 
glycemic control, and renal pathology in established T2DM 
patients in Ibadan, South Western Nigeria.
MaTerials anD MeThODs
subjects
A total of 65 participants were recruited into this case–control 
study. They are comprised of 45 patients with T2DM, recruited 
from the Metabolic Research Ward (MRW) of the University 
College Hospital (UCH), Ibadan, while 20 apparently healthy 
(non-diabetic) individuals age-matched with the cases served as 
controls. All T2DM were on diet and/or oral hypoglycemic drugs. 
They also received regular health education talks. The percent-
age level of glycated hemoglobin was used to classify the T2MD 
patients into three sub-groups: good control (A), fair control (B), 
and poor control (C). Smokers, alcoholics, pregnant women, 
lactating mothers, and those who did not give informed consent 
were excluded from the study. Information on demography was 
obtained using a semi-structured questionnaire. The study was 
approved by the UI/UCH Joint Ethics Committee.
anthropometric Measurement
Height
This was measured using a stadiometer, and the readings recorded 
in meters.
Body Weight
This was determined with Omron weighing scale (HBF, 202) 
placed on a flat surface, and the readings were recorded to the 
nearest 0.5 kg.
Body Mass Index
This was calculated as the ratio of body weight to the square of the 
height in meter; BMI (kilograms per square meter) = body weight 
(kilograms)/height2 (square meter).
Blood Pressure
The blood pressure (BP) of the participants was measured by using 
standard mercury sphygmomanometer after 10 min of rest. The 
readings were recorded to the nearest (millimeter of mercury). 
This was taken for each patient at sitting position.
sample collection
Blood Samples
After an overnight fast of at least 10 h, 10 ml of venous blood was 
obtained from the ante cubical fossa of each participant using a 
sterile needle and syringe and dispensed into appropriate sample 
bottles. Two milliliters were dispensed into EDTA bottle for 
HbA1c determination. Five milliliters were dispensed into lithium 
heparin bottle for cadmium, creatinine, and zinc determinations, 
while the rest was dispensed into fluoride oxalate bottle for 
glucose estimation. Plasma samples were appropriately obtained 
and stored at −20°C until analysis. Whole blood used for HbA1c 
analysis was stored at 4°C for 10 days.
TaBle 1 | classification of glycemic control in diabetics.
group hba1c (%) number of subject
Good control <6.5% 20 (44.4%)
Fairly good control 6.5–7.9% 11 (24.4%)
Poor control ≥8.0% 14 (31.1%)
Total – 65 (100%)
HbA1c, glycated hemoglobin.
TaBle 2 | Demographic indices and anthropometric measurements of 
diabetics and controls.
indices Diabetic (n = 45) control (n = 20) t-value p-value
Age (year) 61.51 ± 8.527 57.35 ± 9.659 1.660 0.106
BMI (kg/m2) 26.027 ± 3.864 25.073 ± 3.884 0.915 0.366
SBP (mmHg) 130.78 ± 16.176 135.89 ± 16.295 1.067 0.293
DBP (mmHg) 79.41 ± 9.370 79.17 ± 11.147 0.077 0.939
n, number of subjects; BMI, body mass index; SPB, systolic blood pressure; DBP, 
diastolic blood pressure.
TaBle 3 | Plasma creatinine and urinary creatinine, microalbumin, 
albumin–creatinine ratio (acr), and estimated glomerular filtration 
rate (egFr) in diabetics and controls.
indices Diabetics  
(n = 45)
controls  
(n = 20)
t-value p-value
Plasma creatinine 
(mg/dl)
1.34 ± 0.29 1.43 ± 0.18 1.47 0.146
Urinary creatinine 
(mg/dl)
85.33 ± 32.91 115.25 ± 47.58 2.554 0.017*
Microalbumin  
(mg/dl)
1.49 ± 0.60 1.03 ± 0.53 3.109 0.003*
Albumin–creatinine 
ratio (mg/g) 
17.44 ± 18.08 8.89 ± 11.16 2.709 0.009*
eGFR (ml/
min/1.73 m2)
59.78 ± 13.83 55.69 ± 9.91 1.354 0.182
*Significant (p < 0.05).
n, number of participants; eGFR, estimated glomerular filtration rate.
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Urine Samples
About 10  ml of spot urine sample was obtained from each 
participant into sterile universal bottles and stored at −4°C until 
analyzed. Urine samples were used for the determination of 
urinary microalbumin and creatinine.
Biochemical assays
Determination of Plasma Cadmium and Zinc
Atomic absorption spectrophotometric (AAS) technique was 
used for the determination of cadmium and zinc using Bulk 
Scientific, 210 VGP model Atomic Absorption Spectrophotometer 
(Germany). Plasma Cd was determined following the method 
of Robert and Clark (16); plasma was used instead of serum to 
ensure adequate stoichiometric relationship to Zn. Zinc was 
determined according to the method of Smith et al. (17).
Plasma Glucose Determination
Fasting plasma glucose (FPG) was determined using glucose 
oxidase method (18), using Dialab Diagnostic reagent kits 
(Gessellschaft m.b.H A-1160 Wienpanikengasse, Austria).
Glycosylated Hemoglobin (HbA1c) Determination
HbA1c was determined using boronate affinity assay method 
as described by Jeppsson et al. (19). NycoCard HbA1c analyzer, 
which is a rapid in vitro method for the measurement of glycated 
hemoglobin (% HbA1c) in human whole blood, was used.
Determination of Microalbumin
Urinary microalbumin was determined using immunoturbidi-
metric assay method (20).
Determination of Plasma Creatinine
Urinary and plasma creatinine were determined by colorimetric 
method (Jaffe’s reaction without deproteinization) according to 
the methods of Bartels et al. (21) and Henry et al. (22).
Urinary Albumin/Creatinine Ratio
This was calculated using the formula below:
 Microalbumin mg/dl)/creatinine mg/dl) UACR mg/g).( ( (× =1000  
Estimated Glomerular Filtration Rate
This was calculated using the Modification of Diet in Renal 
Disease (MDRD) study formula as given below (23):
 
MDRD plasma creatinine age
if bl
= × ×
×
− −186
1 212
1 154 0 203( ) ( )
( .
. .
ack if female)) ( .× 0 742  
statistical analyses
Data analysis was conducted out using SPSS version 21.0. Results 
were expressed as mean ±  SEM. Student’s t-test was used to 
determine significant differences between the means values; 
analysis of variance (ANOVA) was used to compare means across 
groups. Relationship between parameters was assessed using 
Pearson’s correlation coefficient. p value of <0.05 was considered 
significant.
resUlTs
Out of the total 45 diabetics studied, 44.4% had good glycemic 
control, while 24.4% exhibited fair glycemic control and 31.1% 
demonstrated poor glycemic controlled (Table 1). There were no 
statistically significant differences found in the mean age, BMI, 
and systolic and diastolic BP between diabetics and the non-
diabetic groups (Table 2).
Urinary creatinine was significantly lower in diabetics than 
in non-diabetics (p < 0.017). The microalbumin and albumin/
creatinine ratio, in contrast, was significantly higher in diabet-
ics than in non-diabetics. All other parameters were similar 
(p > 0.05) (Table 3). Cadmium and cadmium–zinc ratio demon-
strated significantly lower levels in diabetics than non-diabetics 
and were significantly lower in diabetics than in non-diabetics 
(p  <  0.001). Contrary to expectation, Zn level was not sig-
nificantly higher in diabetics than in non-diabetics, while FPG 
level was significantly higher in diabetics than in non-diabetics 
(p < 0.001) (Table 4).
TaBle 5 | correlation of cadmium with biochemical indices.
Parameters r-value p-value
Fasting plasma glucose (mg/dl) −0.198 0.133
HbA1c (%) −0.007 0.967
Zinc (μg/dl) −0.317 0.014*
Plasma creatinine (mg/dl) 0.149 0.258
Urinary albumin–creatinine ratio (mg/g) −0.172 0.198
eGFR (ml/min/1.73 m2) −0.127 0.338
*Significant (p < 0.05).
HbA1c, glycated hemoglobin; eGFR, estimated glomerular filtration rate.
TaBle 4 | Fasting plasma glucose, cadmium, zinc, and cd/Zn ratio in 
diabetics and non-diabetic (controls).
Diabetics  
(n = 45)
controls  
(n = 20)
t-value p-value
FPG (mg/dl) 150.903 ± 79.394 96.620 ± 11.957 4.474 0.000*
Cadmium (μg/dl) 0.050 ± 0.0201 0.095 ± 0.0311 5.763 0.000*
Zinc (μg/dl) 102.51 ± 10.11 98.1 ± 10.76 1.496 0.144
Cd/Zn ratio 0.002 ± 0.000 0.004 ± 0.001 5.485 0.000*
*Significant (p < 0.05).
p, probability; FPG, fasting plasma glucose.
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Correlation studies showed that cadmium was significantly 
and inversely correlated with zinc (r  =  −0.317, p  <  0.01) 
(Table  5). Cadmium was also inversely correlated with FPG, 
HbA1c,  albumin–creatinine ratio, and eGFR, but all did not 
reach significant levels (p > 0.05) in the cases (Table 5). Other 
parameters were similar.
DiscUssiOn
The contribution to the evolution and complications of metabolic 
disorders by modern environmental health hazards (MEHHs) 
is at the moment poorly recognized. But it is a reality we can-
not escape from. The contribution of key environment toxicant 
cadmium to metabolic disorders, such as DM and metabolic bone 
disease, though referred to in pockets, deserves greater atten-
tion to avoid their emergence into problems requiring extreme 
public health intervention. Type II DM has been associated with 
a combination of genetic, lifestyle, and environmental factors. 
Though, factors such as obesity, BMI, diet, and lifestyle have 
been primarily identified as major risk factors for diabetes, 
environmental pollutants have also been suggested as possible 
link to diabetes, of which cadmium has been one of the most 
strongly implicated (8).
The significant increase in FPG level in diabetics compared 
to the non-diabetics is not unexpected. It is not surprising as 
DM is characterized by persistent hyperglycemia and is the most 
prominent disease related to failure of blood glucose homeo-
stasis. An earlier study from this environment (7) also showed 
significantly higher fasting blood glucose in diabetics than in 
non-diabetics.
Interestingly, cadmium was found in this study to be signifi-
cantly lower in diabetics compared with non-diabetics (p = 0.000). 
This may largely have arisen from the effect of the regular health 
education given to the diabetics embracing better nutrition 
including sources of Zn. This contradicts the observation of 
earlier investigators (7, 24). They reported higher cadmium 
levels in diabetics compared with the non-diabetics. Our posi-
tion may be partly attributed to the observed higher zinc level 
in diabetics compared with non-diabetics though it did not 
reach significant level. Mutual antagonism is a well-established 
relationship between cadmium and zinc (25). The two metals 
are known to compete for common metabolic pathways, such 
as binding sites on metallothionein, a common binding protein 
for cadmium and zinc. This implies that as the zinc level is 
increasing, the cadmium level will be decreasing as evidenced 
in this study. The metallokinetics may, indeed at least in part, 
account for the non-significant difference in the diabetics and 
non-diabetics.
The significant inverse correlation between zinc and cadmium 
in this study could be reflective of metabolic modulation or due 
to decreased Zn bioavailability and absorption as a result of the 
competition of cadmium with zinc. This was also corroborated 
by the cadmium:zinc ratio, which was significantly lower in dia-
betics than in non-diabetics. This suggests that zinc may have a 
profound modulating effect on cadmium toxicity. It has been con-
sistently demonstrated that non-essential toxicant metals mimic 
essential metals and consequently gain access to, and disrupt, key 
cellular functions (26, 27). This study appears to have elegantly 
upheld this seminal observation. It is an important concept that 
could be explored to ameliorate MEHHs as illustrated between 
Cd and Zn in this report. The observed significant reduction in 
urinary creatinine, while microalbumin and albumin:creatinine 
ratio increased in diabetics compared to non-diabetics (p < 0.05), 
may all be indicative of impaired renal function. Cadmium is an 
established nephrotoxicant. The combined effect of the lung-term 
renal impairment of DM and that of Cd may be additive and may 
be a plausible explanation here. This may lead to accelerated 
renal impairment in DM in this population. This agrees with 
the earlier findings of Schrijvers et  al. (28) as well as Edwards 
and Prozialeck (8) who reported that diabetic nephropathy was 
associated with microalbuminuria. DM is one of the primary 
risk factors for developing renal impairment globally (29, 30). 
Both type 1 and type 2 DM may lead to chronic complication 
of diabetic nephropathy (31). Urine microalbumin and urine 
albumin creatinine ratio have all been reported as sensitive and 
early indicators of renal impairment (32). The significantly higher 
albumin:creatinine ratio was significant in diabetics compared 
to non-diabetics (p = 0.009), and the negative correlation with 
cadmium, though not significantly (p > 0.05), may be partially 
corroborative of the microalbuminuria data. Although previous 
studies have associated high blood cadmium level in microalbu-
minuria, in this study, lower levels of cadmium were found in the 
diabetics. Studies have shown early adverse health effects at much 
lower levels of cadmium exposure than previously reported (33).
The significantly raised microalbuminuria seen in the 
diabetics here may be multifactorial, the cadmium effects with 
other confounders, such as age and sex, as kidney function 
declines with age (34), and cadmium, a cumulative toxicant 
is also known to accumulate with age. The significant positive 
correlation of BMI with systolic BP (r  =  0.281; p  =  0.048) 
and non-significantly with diastolic BP (r =  0.236; p =  0.10) 
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probably confirms this well-known relationship in the face of an 
environmental assault. This is in agreement with the observation 
of Mungreiphy et al. (35), who reported a significant positive cor-
relation between mean systolic and diastolic BPs among different 
BMI categories. They suggested that both systolic and diastolic 
BP increased with increase in BMI level. A number of other 
investigators have concluded that among many relevant factors, 
BMI is one of the most important predictors of BP (36–39). 
This may be partly attributed to the role of body weight in the 
pathogenesis of hypertension. Recent studies have shown that 
increase in body weight affects the activities of the adipocytes 
and the secretion of adipokines (leptin and adiponectin). These 
adipokines affect the development of hypertension (40). The 
role of an environmental toxicant, such as Cd which though 
in the past related to hypertension through sodium exchange 
mechanisms, is incompletely elucidated.
The similar plasma creatinine, eGFR levels, and indices of 
renal function found in diabetics and non-diabetics may be due 
to the ameliorating effect of Zn on Cd. The small sample size of 
the current study may also be contributory to the equivocal find-
ings in certain respect. A larger sample size may bring out the true 
situation of the role of this environmental pollutant on metabolic 
disease and in organs that have metabolic roles and lead to meta-
bolic disorders when diseased, such as the kidney. This may lead 
to renal osteodystrophy, a renal induced bone disease that may be 
secondary to the adverse effect of Cd on the kidney.
Good glycemic control is required for the proper manage-
ment of DM. Studies have shown an association between good 
glycemic control and renal function (41, 42), which may be 
altered by a toxicant induced renal impairment. The significant 
decrease in the plasma glucose of patients with good glycemic 
control compared to patients with fair or poor glycemic controls 
may not be unrelated to the relationship between Cd and Zn. The 
HbA1c negatively correlates with plasma cadmium level though 
not significantly and suggest a trend that may be significant 
with larger population. Data from this study also revealed that 
microalbuminuria was higher in the diabetics with poor gly-
cemic control compared to those with good glycemic control. 
This may also allude to a role for the environmental pollutant 
Cd. A better glycemic control is helpful in the prevention of 
nephropathy and other microvascular complications of DM (43). 
The Diabetes Control and Complications Trial (DCCT) showed 
that a target HbA1c level of 7% (vs. 9%) over 9 years reduced the 
risk of microalbuminuria and macroalbuminuria by 34 and 56%, 
respectively (44). Thus, a good glycemic control may have the 
benefit of reducing microalbuminuria in diabetes, which may in 
turn be related to the stoichiometric relationship between Cd and 
Zn. There appears to be a deterioration of glycemic control with 
rise in cadmium level, as suggested by the lower cadmium level 
in participants with good glycemic control compared to the fair 
glycemic and poor glycemic control in this study.
cOnclUsiOn
This report presents evidence of renal function deterioration 
in diabetes, as evidenced by the decreased urinary creatinine 
and increased microalbuminuria and albumin/creatinine ratio. 
Glycemic control may be affected with rise in cadmium level. 
Thus, a good glycemic control may be helpful in the prevention 
of nephropathy and other microvascular complications of DM. 
This may be achievable by reducing Cd exposure and/or by 
modulating the stoichiometric relationship between Cd and Zn, 
which appears to be a critical factor in appropriate management 
of MEHHs. This study therefore suggests that routine assess-
ment of kidney function should be included in the monitoring 
of diabetics. Considering the low concentrations of blood Zn 
levels found in the diabetic patients examined in this study, a Zn 
supplementation may provide a significant protection against 
diabetes-induced complications.
limitation
The small sample size of the current study may in part be con-
tributory to the equivocal findings in certain respect in this study. 
A larger sample size may bring out the true situation of the role of 
this environmental pollutant on metabolic diseases and in organs 
that have metabolic roles and lead to metabolic disorders when 
diseased, such as the kidney.
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